Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBT 006

Next Previous
Drug Profile

CBT 006

Alternative Names: CBT-006

Latest Information Update: 15 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cloudbreak therapeutics
  • Class Anti-inflammatories; Eye disorder therapies
  • Mechanism of Action Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Meibomianitis

Most Recent Events

  • 17 May 2022 Cloudbreak Therapeutics completes a phase II trial in Meibomianitis in USA (Ophthalmic) (NCT04884243)
  • 12 May 2021 Cloudbreak Therapeutics plans a phase II trial for Maeibomianitis, in June 2021 (NCT04884243)
  • 01 May 2021 Clinical trials in Meibomianitis in USA (Ophthalmic) (Cloudbreak Therapeutics pipeline, May 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top